171 related articles for article (PubMed ID: 20308604)
1. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL
Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604
[TBL] [Abstract][Full Text] [Related]
2. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.
Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F
Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023
[TBL] [Abstract][Full Text] [Related]
6. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.
Stasi C; Triboli E; Arena U; Urraro T; Petrarca A; Gragnani L; Laffi G; Zignego AL
J Transl Med; 2014 Jan; 12():21. PubMed ID: 24456582
[TBL] [Abstract][Full Text] [Related]
7. [Current therapeutic strategies for HCV-associated cryoglobulinemia].
Iannuzzella F; Garini G
Reumatismo; 2008; 60(3):163-73. PubMed ID: 18854876
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion in the treatment of mixed cryoglobulinemia.
Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G
Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease.
Lake-Bakaar G; Dustin L; McKeating J; Newton K; Freeman V; Frost SD
Blood; 2007 Jan; 109(2):845-6. PubMed ID: 17210867
[No Abstract] [Full Text] [Related]
12. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.
Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
15. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
[TBL] [Abstract][Full Text] [Related]
16. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
[TBL] [Abstract][Full Text] [Related]
17. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab.
Uppal R; Charles E; Lake-Bakaar G
J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia.
Sansonno D; Tucci FA; Troiani L; Sansonno L; Dammacco F
Curr Med Chem; 2008; 15(2):117-26. PubMed ID: 18220767
[TBL] [Abstract][Full Text] [Related]
19. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
20. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
Cacoub P; Terrier B; Saadoun D
Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
